AustralieFrV1, PubMed, Checkpoint, bibRecord, 003A11

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Identifieur interne : 003A11 ( PubMed/Checkpoint ); précédent : 003A10; suivant : 003A12

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Auteurs : B E De Galan [Australie] ; S. Zoungas [Australie] ; J. Chalmers [Australie] ; C. Anderson [Australie] ; C. Dufouil [France] ; A. Pillai [Australie] ; M. Cooper [Australie] ; D E Grobbee [Pays-Bas] ; M. Hackett [Australie] ; P. Hamet [Canada] ; S R Heller [Royaume-Uni] ; L. Lisheng [République populaire de Chine] ; S. Macmahon [Australie] ; G. Mancia [Italie] ; B. Neal [Australie] ; C Y Pan [République populaire de Chine] ; A. Patel [Australie] ; N. Poulter [Royaume-Uni] ; F. Travert [France] ; M. Woodward [Australie]

Source :

Diabetologia [ 1432-0428 ] ; 2009.

RBID : pubmed:19688336

Descripteurs français

KwdFr :
- Accident vasculaire cérébral (épidémiologie), Angiopathies diabétiques (), Angiopathies diabétiques (épidémiologie), Antihypertenseurs (usage thérapeutique), Association de médicaments, Association médicamenteuse, Cognition (), Diabète de type 2 (), Diabète de type 2 (mortalité), Diabète de type 2 (psychologie), Diabète de type 2 (sang), Facteurs de risque, Femelle, Gliclazide (usage thérapeutique), Humains, Hypoglycémiants (usage thérapeutique), Hypoglycémie (épidémiologie), Indapamide (usage thérapeutique), Infarctus du myocarde (épidémiologie), Mâle, Niveau d'instruction, Périndopril (usage thérapeutique), Questionnaire sur l'état mental de Kahn, Sujet âgé, Troubles de la cognition ().
MESH :
- mortalité : Diabète de type 2.
- psychologie : Diabète de type 2.
- sang : Diabète de type 2.
- usage thérapeutique : Antihypertenseurs, Gliclazide, Hypoglycémiants, Indapamide, Périndopril.
- épidémiologie : Accident vasculaire cérébral, Angiopathies diabétiques, Hypoglycémie, Infarctus du myocarde.
- Angiopathies diabétiques, Association de médicaments, Association médicamenteuse, Cognition, Diabète de type 2, Facteurs de risque, Femelle, Humains, Mâle, Niveau d'instruction, Questionnaire sur l'état mental de Kahn, Sujet âgé, Troubles de la cognition.

English descriptors

KwdEn :
- Aged, Antihypertensive Agents (therapeutic use), Cognition (drug effects), Cognition Disorders (complications), Diabetes Mellitus, Type 2 (blood), Diabetes Mellitus, Type 2 (complications), Diabetes Mellitus, Type 2 (mortality), Diabetes Mellitus, Type 2 (psychology), Diabetic Angiopathies (epidemiology), Diabetic Angiopathies (prevention & control), Drug Combinations, Drug Therapy, Combination, Educational Status, Female, Gliclazide (therapeutic use), Humans, Hypoglycemia (epidemiology), Hypoglycemic Agents (therapeutic use), Indapamide (therapeutic use), Male, Mental Status Schedule, Myocardial Infarction (epidemiology), Perindopril (therapeutic use), Risk Factors, Stroke (epidemiology).
MESH :
- chemical , therapeutic use : Antihypertensive Agents, Gliclazide, Hypoglycemic Agents, Indapamide, Perindopril.
- blood : Diabetes Mellitus, Type 2.
- complications : Cognition Disorders, Diabetes Mellitus, Type 2.
- drug effects : Cognition.
- epidemiology : Diabetic Angiopathies, Hypoglycemia, Myocardial Infarction, Stroke.
- mortality : Diabetes Mellitus, Type 2.
- prevention & control : Diabetic Angiopathies.
- psychology : Diabetes Mellitus, Type 2.
- Aged, Drug Combinations, Drug Therapy, Combination, Educational Status, Female, Humans, Male, Mental Status Schedule, Risk Factors.

Abstract

The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.

DOI: 10.1007/s00125-009-1484-7
PubMed: 19688336

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003C08
to stream PubMed, to step Curation: 003A63

Links to Exploration step

pubmed:19688336

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.</title>
<author><name sortKey="De Galan, B E" sort="De Galan, B E" uniqKey="De Galan B" first="B E" last="De Galan">B E De Galan</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zoungas, S" sort="Zoungas, S" uniqKey="Zoungas S" first="S" last="Zoungas">S. Zoungas</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia. szoungas@george.org.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J" last="Chalmers">J. Chalmers</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anderson, C" sort="Anderson, C" uniqKey="Anderson C" first="C" last="Anderson">C. Anderson</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dufouil, C" sort="Dufouil, C" uniqKey="Dufouil C" first="C" last="Dufouil">C. Dufouil</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM U708, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U708, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pillai, A" sort="Pillai, A" uniqKey="Pillai A" first="A" last="Pillai">A. Pillai</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, M" sort="Cooper, M" uniqKey="Cooper M" first="M" last="Cooper">M. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart Research Institute, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart Research Institute, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grobbee, D E" sort="Grobbee, D E" uniqKey="Grobbee D" first="D E" last="Grobbee">D E Grobbee</name>
<affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hackett, M" sort="Hackett, M" uniqKey="Hackett M" first="M" last="Hackett">M. Hackett</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hamet, P" sort="Hamet, P" uniqKey="Hamet P" first="P" last="Hamet">P. Hamet</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Heller, S R" sort="Heller, S R" uniqKey="Heller S" first="S R" last="Heller">S R Heller</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lisheng, L" sort="Lisheng, L" uniqKey="Lisheng L" first="L" last="Lisheng">L. Lisheng</name>
<affiliation wicri:level="3"><nlm:affiliation>Chinese Hypertension League Institute, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chinese Hypertension League Institute, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Macmahon, S" sort="Macmahon, S" uniqKey="Macmahon S" first="S" last="Macmahon">S. Macmahon</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mancia, G" sort="Mancia, G" uniqKey="Mancia G" first="G" last="Mancia">G. Mancia</name>
<affiliation wicri:level="3"><nlm:affiliation>University of Milan-Bicocca and San Gerardo Hospital, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University of Milan-Bicocca and San Gerardo Hospital, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neal, B" sort="Neal, B" uniqKey="Neal B" first="B" last="Neal">B. Neal</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pan, C Y" sort="Pan, C Y" uniqKey="Pan C" first="C Y" last="Pan">C Y Pan</name>
<affiliation wicri:level="3"><nlm:affiliation>Chinese People's Liberation Army General Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chinese People's Liberation Army General Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, A" sort="Patel, A" uniqKey="Patel A" first="A" last="Patel">A. Patel</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poulter, N" sort="Poulter, N" uniqKey="Poulter N" first="N" last="Poulter">N. Poulter</name>
<affiliation wicri:level="3"><nlm:affiliation>Imperial College and St Mary's Hospital, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial College and St Mary's Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Travert, F" sort="Travert, F" uniqKey="Travert F" first="F" last="Travert">F. Travert</name>
<affiliation wicri:level="3"><nlm:affiliation>UPMC University of Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UPMC University of Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Woodward, M" sort="Woodward, M" uniqKey="Woodward M" first="M" last="Woodward">M. Woodward</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19688336</idno>
<idno type="pmid">19688336</idno>
<idno type="doi">10.1007/s00125-009-1484-7</idno>
<idno type="wicri:Area/PubMed/Corpus">003C08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003C08</idno>
<idno type="wicri:Area/PubMed/Curation">003A63</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A63</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003A63</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A63</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.</title>
<author><name sortKey="De Galan, B E" sort="De Galan, B E" uniqKey="De Galan B" first="B E" last="De Galan">B E De Galan</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Zoungas, S" sort="Zoungas, S" uniqKey="Zoungas S" first="S" last="Zoungas">S. Zoungas</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia. szoungas@george.org.au.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J" last="Chalmers">J. Chalmers</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anderson, C" sort="Anderson, C" uniqKey="Anderson C" first="C" last="Anderson">C. Anderson</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dufouil, C" sort="Dufouil, C" uniqKey="Dufouil C" first="C" last="Dufouil">C. Dufouil</name>
<affiliation wicri:level="3"><nlm:affiliation>INSERM U708, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U708, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pillai, A" sort="Pillai, A" uniqKey="Pillai A" first="A" last="Pillai">A. Pillai</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cooper, M" sort="Cooper, M" uniqKey="Cooper M" first="M" last="Cooper">M. Cooper</name>
<affiliation wicri:level="1"><nlm:affiliation>Baker IDI Heart Research Institute, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Baker IDI Heart Research Institute, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Grobbee, D E" sort="Grobbee, D E" uniqKey="Grobbee D" first="D E" last="Grobbee">D E Grobbee</name>
<affiliation wicri:level="3"><nlm:affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</nlm:affiliation>
<country xml:lang="fr" wicri:curation="lc">Pays-Bas</country>
<wicri:regionArea>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht</wicri:regionArea>
<placeName><settlement type="city">Utrecht</settlement>
<region nuts="2" type="province">Utrecht (province)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hackett, M" sort="Hackett, M" uniqKey="Hackett M" first="M" last="Hackett">M. Hackett</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hamet, P" sort="Hamet, P" uniqKey="Hamet P" first="P" last="Hamet">P. Hamet</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Heller, S R" sort="Heller, S R" uniqKey="Heller S" first="S R" last="Heller">S R Heller</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield</wicri:regionArea>
<wicri:noRegion>Sheffield</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lisheng, L" sort="Lisheng, L" uniqKey="Lisheng L" first="L" last="Lisheng">L. Lisheng</name>
<affiliation wicri:level="3"><nlm:affiliation>Chinese Hypertension League Institute, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chinese Hypertension League Institute, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Macmahon, S" sort="Macmahon, S" uniqKey="Macmahon S" first="S" last="Macmahon">S. Macmahon</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mancia, G" sort="Mancia, G" uniqKey="Mancia G" first="G" last="Mancia">G. Mancia</name>
<affiliation wicri:level="3"><nlm:affiliation>University of Milan-Bicocca and San Gerardo Hospital, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>University of Milan-Bicocca and San Gerardo Hospital, Milan</wicri:regionArea>
<placeName><settlement type="city">Milan</settlement>
<region nuts="2">Lombardie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neal, B" sort="Neal, B" uniqKey="Neal B" first="B" last="Neal">B. Neal</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pan, C Y" sort="Pan, C Y" uniqKey="Pan C" first="C Y" last="Pan">C Y Pan</name>
<affiliation wicri:level="3"><nlm:affiliation>Chinese People's Liberation Army General Hospital, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Chinese People's Liberation Army General Hospital, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, A" sort="Patel, A" uniqKey="Patel A" first="A" last="Patel">A. Patel</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Poulter, N" sort="Poulter, N" uniqKey="Poulter N" first="N" last="Poulter">N. Poulter</name>
<affiliation wicri:level="3"><nlm:affiliation>Imperial College and St Mary's Hospital, London, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Imperial College and St Mary's Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Travert, F" sort="Travert, F" uniqKey="Travert F" first="F" last="Travert">F. Travert</name>
<affiliation wicri:level="3"><nlm:affiliation>UPMC University of Paris, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>UPMC University of Paris, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Woodward, M" sort="Woodward, M" uniqKey="Woodward M" first="M" last="Woodward">M. Woodward</name>
<affiliation wicri:level="4"><nlm:affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050</wicri:regionArea>
<orgName type="university">Université de Sydney</orgName>
<placeName><settlement type="city">Sydney</settlement>
<region type="état">Nouvelle-Galles du Sud</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Diabetologia</title>
<idno type="eISSN">1432-0428</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antihypertensive Agents (therapeutic use)</term>
<term>Cognition (drug effects)</term>
<term>Cognition Disorders (complications)</term>
<term>Diabetes Mellitus, Type 2 (blood)</term>
<term>Diabetes Mellitus, Type 2 (complications)</term>
<term>Diabetes Mellitus, Type 2 (mortality)</term>
<term>Diabetes Mellitus, Type 2 (psychology)</term>
<term>Diabetic Angiopathies (epidemiology)</term>
<term>Diabetic Angiopathies (prevention & control)</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Educational Status</term>
<term>Female</term>
<term>Gliclazide (therapeutic use)</term>
<term>Humans</term>
<term>Hypoglycemia (epidemiology)</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Indapamide (therapeutic use)</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Myocardial Infarction (epidemiology)</term>
<term>Perindopril (therapeutic use)</term>
<term>Risk Factors</term>
<term>Stroke (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Accident vasculaire cérébral (épidémiologie)</term>
<term>Angiopathies diabétiques ()</term>
<term>Angiopathies diabétiques (épidémiologie)</term>
<term>Antihypertenseurs (usage thérapeutique)</term>
<term>Association de médicaments</term>
<term>Association médicamenteuse</term>
<term>Cognition ()</term>
<term>Diabète de type 2 ()</term>
<term>Diabète de type 2 (mortalité)</term>
<term>Diabète de type 2 (psychologie)</term>
<term>Diabète de type 2 (sang)</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Gliclazide (usage thérapeutique)</term>
<term>Humains</term>
<term>Hypoglycémiants (usage thérapeutique)</term>
<term>Hypoglycémie (épidémiologie)</term>
<term>Indapamide (usage thérapeutique)</term>
<term>Infarctus du myocarde (épidémiologie)</term>
<term>Mâle</term>
<term>Niveau d'instruction</term>
<term>Périndopril (usage thérapeutique)</term>
<term>Questionnaire sur l'état mental de Kahn</term>
<term>Sujet âgé</term>
<term>Troubles de la cognition ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antihypertensive Agents</term>
<term>Gliclazide</term>
<term>Hypoglycemic Agents</term>
<term>Indapamide</term>
<term>Perindopril</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Cognition Disorders</term>
<term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cognition</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Diabetic Angiopathies</term>
<term>Hypoglycemia</term>
<term>Myocardial Infarction</term>
<term>Stroke</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Diabetic Angiopathies</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Diabète de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antihypertenseurs</term>
<term>Gliclazide</term>
<term>Hypoglycémiants</term>
<term>Indapamide</term>
<term>Périndopril</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Accident vasculaire cérébral</term>
<term>Angiopathies diabétiques</term>
<term>Hypoglycémie</term>
<term>Infarctus du myocarde</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Combinations</term>
<term>Drug Therapy, Combination</term>
<term>Educational Status</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Angiopathies diabétiques</term>
<term>Association de médicaments</term>
<term>Association médicamenteuse</term>
<term>Cognition</term>
<term>Diabète de type 2</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Niveau d'instruction</term>
<term>Questionnaire sur l'état mental de Kahn</term>
<term>Sujet âgé</term>
<term>Troubles de la cognition</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19688336</PMID>
<DateCreated><Year>2009</Year>
<Month>10</Month>
<Day>08</Day>
</DateCreated>
<DateCompleted><Year>2010</Year>
<Month>04</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>17</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>52</Volume>
<Issue>11</Issue>
<PubDate><Year>2009</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Diabetologia</Title>
<ISOAbbreviation>Diabetologia</ISOAbbreviation>
</Journal>
<ArticleTitle>Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.</ArticleTitle>
<Pagination><MedlinePgn>2328-2336</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-009-1484-7</ELocationID>
<Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n = 8,689), 24-27 ('mild dysfunction', n = 2,231) and <24 ('severe dysfunction', n = 212). Risks of major cardiovascular events, death and hypoglycaemia and interactions with treatment were assessed using Cox proportional hazards analysis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Relative to normal function, both mild and severe cognitive dysfunction significantly increased the multiple-adjusted risks of major cardiovascular events (HR 1.27, 95% CI 1.11-1.46 and 1.42, 95% CI 1.01-1.99; both p < 0.05), cardiovascular death (1.41, 95% CI 1.16-1.71 and 1.56, 95% CI 0.99-2.46; both p </AbstractText>
<AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">Cognitive dysfunction is an independent predictor of clinical outcomes in patients with type 2 diabetes, but does not modify the effects of BP lowering or glucose control on the risks of major cardiovascular events.</AbstractText>
<AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00145925.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Galan</LastName>
<ForeName>B E</ForeName>
<Initials>BE</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zoungas</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia. szoungas@george.org.au.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Monash University, Melbourne, VIC, Australia. szoungas@george.org.au.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chalmers</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anderson</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dufouil</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>INSERM U708, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>UPMC University of Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pillai</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cooper</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Baker IDI Heart Research Institute, Melbourne, VIC, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Grobbee</LastName>
<ForeName>D E</ForeName>
<Initials>DE</Initials>
<AffiliationInfo><Affiliation>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hackett</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hamet</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Centre Hospitalier de l'Université de Montreal and Université de Montreal, Montreal, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Heller</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
<AffiliationInfo><Affiliation>University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lisheng</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Chinese Hypertension League Institute, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>MacMahon</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mancia</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>University of Milan-Bicocca and San Gerardo Hospital, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Neal</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pan</LastName>
<ForeName>C Y</ForeName>
<Initials>CY</Initials>
<AffiliationInfo><Affiliation>Chinese People's Liberation Army General Hospital, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Patel</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poulter</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Imperial College and St Mary's Hospital, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Travert</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>UPMC University of Paris, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Woodward</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>The George Institute for International Health, The University of Sydney, PO Box M201, Missenden Road, Camperdown, Sydney, NSW, 2050, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Mount Sinai School of Medicine, New York, NY, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>ADVANCE Collaborative group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00145925</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>08</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Diabetologia</MedlineTA>
<NlmUniqueID>0006777</NlmUniqueID>
<ISSNLinking>0012-186X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C494243">indapamide, perindopril drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F089I0511L</RegistryNumber>
<NameOfSubstance UI="D007190">Indapamide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>G4PX8C4HKV</RegistryNumber>
<NameOfSubstance UI="D005907">Gliclazide</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>Y5GMK36KGY</RegistryNumber>
<NameOfSubstance UI="D020913">Perindopril</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2006 Nov;55(11):2986-92</RefSource>
<PMID Version="1">17065334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med. 1984 Dec;77(6):1043-8</RefSource>
<PMID Version="1">6334441</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 1996 Mar;44(3):237-41</RefSource>
<PMID Version="1">8600190</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 Dec 17;366(9503):2112-7</RefSource>
<PMID Version="1">16360788</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Paediatr Perinat Epidemiol. 2005 Nov;19(6):452-9</RefSource>
<PMID Version="1">16269073</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2001 Sep;44(9):1118-20</RefSource>
<PMID Version="1">11596665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 2003 Oct 28;108(17):2154-69</RefSource>
<PMID Version="1">14581387</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Geriatr. 2006 May 01;6:8</RefSource>
<PMID Version="1">16650284</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2005 Oct;62(10):1539-44</RefSource>
<PMID Version="1">16216936</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aging Clin Exp Res. 2007 Feb;19(1):41-7</RefSource>
<PMID Version="1">17332720</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2000 Jan 24;160(2):174-80</RefSource>
<PMID Version="1">10647755</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Hypertens. 2005 Aug;18(8):1052-9</RefSource>
<PMID Version="1">16109319</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2004 May;27(5):1047-53</RefSource>
<PMID Version="1">15111519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Sep 8;370(9590):829-40</RefSource>
<PMID Version="1">17765963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2005 Dec;48(12):2460-9</RefSource>
<PMID Version="1">16283246</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Epidemiology. 2009 Jan;20(1):100-9</RefSource>
<PMID Version="1">19234402</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Psychiatr Res. 1975 Nov;12(3):189-98</RefSource>
<PMID Version="1">1202204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Endocr Rev. 2008 Jun;29(4):494-511</RefSource>
<PMID Version="1">18436709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1996 Mar 9;312(7031):608-11</RefSource>
<PMID Version="1">8595334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Jun 12;358(24):2560-72</RefSource>
<PMID Version="1">18539916</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2001 Feb;24(2):366-70</RefSource>
<PMID Version="1">11213894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 1993 May 12;269(18):2386-91</RefSource>
<PMID Version="1">8479064</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2005 May 24;64(10):1750-5</RefSource>
<PMID Version="1">15911803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2004 Jul;47(7):1245-1256</RefSource>
<PMID Version="1">15241592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1994 Jun 18;308(6944):1604-8</RefSource>
<PMID Version="1">8025427</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes. 1996 Jan;45(1):86-90</RefSource>
<PMID Version="1">8522065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circulation. 1996 May 15;93(10):1809-17</RefSource>
<PMID Version="1">8635260</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Res Clin Pract. 2009 Mar;83(3):387-93</RefSource>
<PMID Version="1">19157618</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Geriatr Psychiatry. 2003 Sep-Oct;11(5):551-60</RefSource>
<PMID Version="1">14506089</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 1997 May;20(5):792-5</RefSource>
<PMID Version="1">9135944</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2009 Feb;32(2):221-6</RefSource>
<PMID Version="1">19171735</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2009 Aug;52(8):1504-10</RefSource>
<PMID Version="1">19455303</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 1998 May;51(5):385-91</RefSource>
<PMID Version="1">9619965</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003925" MajorTopicYN="N">Diabetic Angiopathies</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005907" MajorTopicYN="N">Gliclazide</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007003" MajorTopicYN="N">Hypoglycemia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007190" MajorTopicYN="N">Indapamide</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008609" MajorTopicYN="N">Mental Status Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020913" MajorTopicYN="N">Perindopril</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>05</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>07</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>8</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2010</Year>
<Month>4</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19688336</ArticleId>
<ArticleId IdType="doi">10.1007/s00125-009-1484-7</ArticleId>
<ArticleId IdType="pii">10.1007/s00125-009-1484-7</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>République populaire de Chine</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Lombardie</li>
<li>Nouvelle-Galles du Sud</li>
<li>Utrecht (province)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Londres</li>
<li>Milan</li>
<li>Paris</li>
<li>Pékin</li>
<li>Sydney</li>
<li>Utrecht</li>
</settlement>
<orgName><li>Université de Sydney</li>
</orgName>
</list>
<tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="De Galan, B E" sort="De Galan, B E" uniqKey="De Galan B" first="B E" last="De Galan">B E De Galan</name>
</region>
<name sortKey="Anderson, C" sort="Anderson, C" uniqKey="Anderson C" first="C" last="Anderson">C. Anderson</name>
<name sortKey="Chalmers, J" sort="Chalmers, J" uniqKey="Chalmers J" first="J" last="Chalmers">J. Chalmers</name>
<name sortKey="Cooper, M" sort="Cooper, M" uniqKey="Cooper M" first="M" last="Cooper">M. Cooper</name>
<name sortKey="Hackett, M" sort="Hackett, M" uniqKey="Hackett M" first="M" last="Hackett">M. Hackett</name>
<name sortKey="Macmahon, S" sort="Macmahon, S" uniqKey="Macmahon S" first="S" last="Macmahon">S. Macmahon</name>
<name sortKey="Neal, B" sort="Neal, B" uniqKey="Neal B" first="B" last="Neal">B. Neal</name>
<name sortKey="Patel, A" sort="Patel, A" uniqKey="Patel A" first="A" last="Patel">A. Patel</name>
<name sortKey="Pillai, A" sort="Pillai, A" uniqKey="Pillai A" first="A" last="Pillai">A. Pillai</name>
<name sortKey="Woodward, M" sort="Woodward, M" uniqKey="Woodward M" first="M" last="Woodward">M. Woodward</name>
<name sortKey="Zoungas, S" sort="Zoungas, S" uniqKey="Zoungas S" first="S" last="Zoungas">S. Zoungas</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Dufouil, C" sort="Dufouil, C" uniqKey="Dufouil C" first="C" last="Dufouil">C. Dufouil</name>
</region>
<name sortKey="Travert, F" sort="Travert, F" uniqKey="Travert F" first="F" last="Travert">F. Travert</name>
</country>
<country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Grobbee, D E" sort="Grobbee, D E" uniqKey="Grobbee D" first="D E" last="Grobbee">D E Grobbee</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Hamet, P" sort="Hamet, P" uniqKey="Hamet P" first="P" last="Hamet">P. Hamet</name>
</noRegion>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Heller, S R" sort="Heller, S R" uniqKey="Heller S" first="S R" last="Heller">S R Heller</name>
</noRegion>
<name sortKey="Poulter, N" sort="Poulter, N" uniqKey="Poulter N" first="N" last="Poulter">N. Poulter</name>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Lisheng, L" sort="Lisheng, L" uniqKey="Lisheng L" first="L" last="Lisheng">L. Lisheng</name>
</noRegion>
<name sortKey="Pan, C Y" sort="Pan, C Y" uniqKey="Pan C" first="C Y" last="Pan">C Y Pan</name>
</country>
<country name="Italie"><region name="Lombardie"><name sortKey="Mancia, G" sort="Mancia, G" uniqKey="Mancia G" first="G" last="Mancia">G. Mancia</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003A11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:19688336
   |texte=   Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:19688336" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki